Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT

PHASE3CompletedINTERVENTIONAL
Enrollment

1,002

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Latent Tuberculosis Infection
Interventions
BEHAVIORAL

Self Administered Therapy (SAT)

Self Administered Therapy (SAT)

BEHAVIORAL

SMS reminders

Short Message Service (SMS) text reminders

DRUG

isoniazid and rifapentine

rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)

Trial Locations (12)

10032

Columbia University College of Physicians and Surgeons and New York City Department of Health, New York

20422

Washington DC Veterans Affairs Medical Center, Washington D.C.

27713

Duke University, Durham

80204

Denver Public Health Department, Denver

94110

University of California, San Francisco, San Francisco

37232-0146

Vanderbilt University Medical Center and Nashville Metro Public Health Department, Nashville

76104-4802

University of North Texas Health Science Center at Fort Worth, Fort Worth

78229-4404

Audie L. Murphy VA Hospital, San Antonio

South Texas - Department of State Health Services, San Antonio

Unknown

TB and Chest service of Hong Kong, Hong Kong

Wits Health Consortium, Soweto

08023

Agencia de Salut Publica - Barcelona, Spain and UNTHSC, Barcelona

All Listed Sponsors
lead

Centers for Disease Control and Prevention

FED

NCT01582711 - Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT | Biotech Hunter | Biotech Hunter